Oxfam response to WTO TRIPS waiver for COVID-19 vaccines being blocked again by rich countries - a massive missed opportunity to speed up and scale up the production of lifesaving vaccines worldwide
- Published:
- Short URL: https://www.oxfam.org.uk/mc/235gtd/
In response to calls for a waiver of Trade Related Intellectual Property Rules (TRIPS) for COVID-19 vaccines, which is backed by more than 100 mostly developing countries, being blocked again at World Trade Organisation talks by rich countries, Oxfam’s Health Policy Manager, Anna Marriott, said:
“This is a massive missed opportunity to speed up and scale up the production of lifesaving vaccines worldwide by waiving the intellectual property barriers that prevent more qualified manufacturers joining the effort.
“Rich countries are vaccinating at a rate of one person per second yet are siding with a handful of pharmaceutical corporations in protecting their monopolies against the needs of the majority of developing countries who are struggling to administer a single dose.
“It is unforgivable that while people are literally fighting for breath, rich country governments continue to block what could be a vital breakthrough in ending this pandemic for everyone in rich and poor countries alike.
“During a pandemic that is devastating lives across the planet, governments should be using their powers now, not tomorrow, to remove intellectual property rules and ensure pharmaceutical companies work together to share technology and fix raw material shortages, all of which are standing in the way of a massive scale up in production.”
/Ends
For more information, or to arrange an interview please contact: Sarah Dransfield, in the Oxfam press office, on + 44 (0)7884 114825 / email sdransfield@oxfam.org.uk
Oxfam is part of The Peoples’ Vaccine Alliance, a coalition of global and national organizations and activists united under a common aim of campaigning for a ‘People’s Vaccine’. The call for a People’s Vaccine is backed by past and present world leaders, health experts, faith leaders and economists. For more information visit: https://peoplesvaccine.org
Press contact
For comments, interviews, or information please contact Sarah Dransfield (Senior Press Officer):